Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
| Study Number Sort descending | Lead Group | Study Title | CIRB | Study Status | |
|---|---|---|---|---|---|
| NRG-GY023 | NRG | A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination with Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women with Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer who have Received Prior Bevacizumab | Adult CIRB - Late Phase Emphasis | Available to Open | |
| NRG-GY024 | NRG | Groningen International Study on Sentinel Nodes in Vulvar Cancer (GROINSS-V) III: A Prospective Phase II Treatment Trial | Adult CIRB - Late Phase Emphasis | Available to Open | |
| NRG-GY025 | NRG | A Randomized Phase II Trial of Nivolumab and Ipilimumab Compared to Nivolumab Monotherapy in Patients with Deficient Mismatch Repair System Recurrent Endometrial Carcinoma | Adult CIRB - Late Phase Emphasis | Available to Open | |
| NRG-GY026 | NRG | A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined with Either Trastuzumab and Hyaluronidase-oysk (HERCEPTIN HYLECTA) or Pertuzumab, Trastuzumab, and Hyaluronidase-zzfx (PHESGO) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma | Adult CIRB - Late Phase Emphasis | Available to Open | |
| NRG-GY027 | NRG | Phase I/IB Safety and Pharmacodynamic Study of Neoadjuvant (NACT) Paclitaxel and Carboplatin with Ipatasertib as Initial Therapy of Ovarian Cancer PTMA 100805 | Adult CIRB - Late Phase Emphasis | Available to Open | |
| NRG-GY028 | NRG | A Phase IB and Randomized Phase II Trial of Megestrol Acetate with or without Ipatasertib in Recurrent or Metastatic Endometrioid Endometrial Cancer | Adult CIRB - Late Phase Emphasis | Available to Open | |
| NRG-GY029 | NRG | A Randomized Phase II Trial Comparing the Combination of PI3K Inhibitor Copanlisib (BAY 80-6946) and PARP Inhibitor Olaparib (AZD2281) to Standard Chemotherapy in Patients with Recurrent Platinum Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer who have Progressed through Prior PARP Inhibitor Therapy | Adult CIRB - Late Phase Emphasis | Available to Open | |
| NRG-GY031 | NRG | A Phase 1B Study of Combination ATR (M1774) and BET Inhibition (ZEN00-3694) to Exploit ARID1A Loss in Recurrent Ovarian and Endometrial Cancer | Adult CIRB - Late Phase Emphasis | Available to Open | |
| NRG-GY032 | NRG | A Phase II Study of Tailored Adjuvant Therapy in Pole-Mutated and p53-Wildtype/NSMP Early-Stage Endometrial Cancer (RAINBO BLUE & TAPER) | Adult CIRB - Late Phase Emphasis | Available to Open | |
| NRG-GY033 | NRG | A Phase II Study of Androgen Receptor (AR) Inhibition by Darolutamide in Combination with Leuprolide Acetate and Exemestane in Recurrent Adult-Type Ovarian Granulosa Cell Tumor | Adult CIRB - Late Phase Emphasis | Available to Open |